Our clinical studies

Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF^V600E mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve

A multicenter, randomized, open-label, 2-arm, Phase II trial with a safety lead-in phase evaluating the combination of encorafenib and cetuximab versus irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI)/cetuximab in Chinese patients with BRAFV600E mutant metastatic colorectal cancer.

An observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.

Phase I dose escalation and dose expansion, international, multicenter study of W0180 as single agent and in combination with pembrolizumab (anti-PD-1) in adult participants with locally advanced or metastatic solid tumors.

Study of the combination of Binimetinib and Encorafenib in adolescent patients with unresectable or Metastatic BRAF V600-mutant Melanoma

Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.

A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants

Etude en double aveugle versus placebo de l'efficacité et de la tolérance de Cirkan® sur la symptomatologie fonctionnelle veineuse éprouvée (C0s à C3s) par les patientes obèses

Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado

Effect of V0251 in acute vertigo. A randomized double blind placebo conrolled study

Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence

Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group

Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline-based adjuvant chemotherapy

Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational single arm study

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure

Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder

A multicenter, open-label, phase 1 study investigating the safety and tolerability of encorafenib monotherapy in BRAF^V600E-mutated Chinese patients with advanced metastatic solid tumors

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides

Etude randomisée, en groupes parallèles, en double insu, de l'efficacité de la méquitazine sur la symptomatologie et l'obstruction nasale chez des patients présentant une rhinite allergique perannuelle

Evaluation Of The Rate Of Pathological Complete Response (pCR) For Neoadjuvant Chemoradiotherapy (CT-RT) And For Chemotherapy (CT) Alone in Locally Advanced Non Small Cell Lung Cancer (LA-NSCLC): A Randomized Phase II trial